title: Is ruxolitinib a potentially useful drug in hematological malignancies with RAS pathway hyperactivation?
authors.affiliation: 5 Medical Department with Hematology, Oncology and Palliative Medicine, Hospital Hietzing, Vienna, Austria klaus.geissler@wienkav.at.
authors.forename: Klaus
authors.initials: K
authors.lastname: Geissler
authors.affiliation: Department of Laboratory Medicine, Medical University of Vienna, Austria.
authors.forename: Eva
authors.initials: E
authors.lastname: Jäger
authors.affiliation: Blood Transfusion Service for Upper Austria, Austrian Red Cross, Linz, Austria.
authors.forename: Agnes
authors.initials: A
authors.lastname: Barna
authors.affiliation: 3 Medical Department, Hanusch Hospital, Vienna, Austria.
authors.forename: Thamer
authors.initials: T
authors.lastname: Sliwa
authors.affiliation: Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Austria.
authors.forename: Paul
authors.initials: P
authors.lastname: Knöbl
authors.affiliation: Department of Laboratory Medicine, Medical University of Vienna, Austria.
authors.forename: Ilse
authors.initials: I
authors.lastname: Schwarzinger
authors.affiliation: Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Austria.
authors.forename: Heinz
authors.initials: H
authors.lastname: Gisslinger
authors.affiliation: Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Austria.
authors.forename: Peter
authors.initials: P
authors.lastname: Valent
mesh_terms: D019337:Hematologic Neoplasms; D006801:Humans; D009196:Myeloproliferative Disorders; D009369:Neoplasms; D009570:Nitriles; D011720:Pyrazoles; D011743:Pyrimidines
chemical_list: D009570:Nitriles; D011720:Pyrazoles; D011743:Pyrimidines; C540383:ruxolitinib
keywords: CMML; JMML; RAS; ruxolitinib